03-11-08





EXPRESS MAIL NO. EV934847599US

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/542,936	
Filing Date	July 19, 2005	
First Named Inventor	Byoung-Joo Gwag	
Art Unit	1649	
Examiner Name	HAYES, Robert Clinton	
Attorney Docket No.	t No. 110200.404USPC	

ENCLOSURES (check all that apply)						
Fee Transmitta Fee Attach Amendment/Re After Final Affidavits/o Extension of Ti Express Aband Request Information Dis Statement and Cited Reference Certified Copy Document(s) Response to M under 37 CFR Response to M Parts/Incomple	declaration(s) me Request donment sclosure Transmittal ses of Priority lissing Parts 1.52 or 1.53	Drawing(s) Request for Correcter Receipt Licensing-related Part Petition Petition to Convert to Provisional Application Power of Attorney, Revocation, Change Correspondence Add Declaration Statement under 37 (3.73(b) Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table	d Filing Ders a of ress CFR G A A A A A A A A A A A A	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Other Enclosure(s) (please Identify below):		
Remarks						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name	Seed Intellectual Property Law Group PLLC		p PLLC	Customer Number 00500		
Signature Roll B. Marky						
Printed Name Richard G. Sharkey, Ph.D.						
Date	Mark 10, 2009 Reg.		Reg. No.	32,629		



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Byoung-Joo GWAG, Sung-Hwa YOON, Sun-Hee KIM and

Seok-Joon WON

Application No.

10/542,936

Confirmation No.

5371

Filed

July 19, 2005

For

METHOD FOR INHIBITION OF NECROSIS INDUCED BY

NEUROTROPHIN

Examiner

HAYES, Ph.D., Robert Clinton

Art Unit

1649

Docket No.

110200.404USPC

Date

March 10, 2008

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO 2nd RESTRICTION REQUIREMENT

Commissioner for Patents:

In response to the Restriction Requirement dated February 25, 2008, Applicants hereby elect Group IIb, claims 14-17, directed to compositions comprising a neurotrophin and a tetrafluorobenzyl derivative, wherein the neurotrophin is BDNF, to initiate examination. The unifying inventive concept of pending claim 14 is the combination of a neurotrophin and a tetrafluorobenzyl derivative. Upon a determination of patentability of the combination wherein the neurotrophin is BDNF, the Examiner is requested to examine claim 14 generally.

Applicants note that an Information Disclosure Statement (IDS) was submitted to the Patent Office on May 19, 2006. A Supplemental Information Disclosure Statement (Supplemental IDS) was submitted on January 3, 2007. Prior to issuing the next Office Action, the Examiner is respectfully asked to make of record the references in the IDS and Supplemental IDS and return an initialed copy of each of these Statements to the undersigned attorney.

Consideration of the elected claims 14-17 is now requested.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Richard G. Sharkey, Ph.D.

Registration No. 32,629

Customer No. 00500

MillicentS/1126251